Related Experiment Video
Updated: Jun 13, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Gene-expression-based prognostic assays for breast cancer
Chungyeul Kim1, Soonmyung Paik
1Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA.
Nature Reviews. Clinical Oncology
|May 5, 2010
Summary
Gene expression tests aid breast cancer prognostication. This review guides oncologists on selecting MammaPrint and Oncotype DX based on their development, technology, and clinical utility.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biotechnology
Background:
- Gene-expression-based laboratory tests are increasingly used for breast cancer prognostication.
- Understanding the development and context of these assays is crucial for clinical oncologists.
- Accurate prognostic information aids in treatment decisions for breast cancer patients.
Purpose of the Study:
- To provide an overview of gene-expression profiling assay development.
- To compare MammaPrint and Oncotype DX assays.
- To guide clinical oncologists in selecting and utilizing these prognostic assays.
Main Methods:
- Review of gene-expression profiling assay development processes.
- Comparative analysis of MammaPrint and Oncotype DX.
- Evaluation of assay technologies and clinical utility.
Main Results:
- Gene-expression assays differ in their development, technology, and clinical applications.
- MammaPrint and Oncotype DX represent distinct approaches to breast cancer prognostication.
- Understanding these differences is key for appropriate clinical use.
Conclusions:
- Gene-expression profiling assays offer valuable prognostic information for breast cancer.
- Oncologists require a clear understanding of assay specifics for optimal patient care.
- This review provides a framework for selecting and applying these advanced diagnostic tools.